| University of California San Francisco | |
|---|---|
| Logo placeholder | |
| Location | San Francisco, CA, USA |
| Type | University |
| Website | https://www.ucsf.edu/ |
| Focus Areas | [Alzheimer's Disease](/diseases/alzheimers), [FTD](/diseases/ftd), Lewy Body Disease |
| Departments | Memory and Aging Center Department of Neurology |
University of California San Francisco (UCSF) is a premier public research university and academic medical center specializing exclusively in health sciences. Based in San Francisco, California, UCSF is consistently ranked among the top medical schools in the United States and has established itself as a global leader in neuroscience research and clinical care for neurodegenerative diseases[1].
The institution is recognized for its contributions to neurodegenerative disease research, with focus areas including Alzheimer's Disease, Frontotemporal Dementia (FTD), and Lewy Body Disease. UCSF hosts 7 researchers tracked in the NeuroWiki database and maintains the Memory and Aging Center and Department of Neurology as dedicated centers for neuroscience research[2].
UCSF's impact on neurodegenerative disease research extends across multiple domains: fundamental neuroscience discovery, biomarker development, clinical trial design, and global brain health initiatives. The institution's Alzheimer's Disease Research Center is funded by the NIH National Institute on Aging (NIA) and collaborates with 35 centers nationwide as part of the NIA's Alzheimer's Disease Research Centers Program[3]. Through its Memory and Aging Center and Department of Neurology, UCSF supports multidisciplinary investigation into the mechanisms, diagnosis, and treatment of neurodegenerative diseases.
UCSF traces its origins to the founding of Toland Medical College in 1873, which later became affiliated with the University of California in 1873. Over its 150-year history, UCSF has grown to become one of the world's leading academic medical centers, with particular strength in neuroscience and brain research[1:1].
The Memory and Aging Center was established in the 1990s to provide comprehensive care for patients with memory disorders while simultaneously advancing research into the causes and treatments of these conditions. Under the leadership of renowned neurologists, the center has become one of the most active dementia research programs in the world. The center houses the UCSF Neurodegenerative Disease Brain Bank, which provides postmortem tissue for research into the neuropathology of Alzheimer's disease, FTD, Lewy body disease, and related conditions[4].
In 2014, UCSF launched the Global Brain Health Institute (GBHI) in partnership with Trinity College Dublin, with the mission of reducing the global burden of dementia through training, research, and policy advocacy[5]. GBHI has trained over 300 brain health leaders from 50 countries and established satellite programs in Ireland, Greece, and multiple countries in Latin America.
The Memory and Aging Center at UCSF represents one of the foremost clinical research programs for neurodegenerative dementias. The center's research portfolio encompasses multiple disease areas and methodological approaches[2:1]:
Alzheimer's Disease Research: UCSF researchers have been pioneers in amyloid and tau PET imaging, developing new tracers and validating their use for early diagnosis and disease staging[6][7]. The center leads the New IDEAS study, a landmark investigation of over 25,000 participants examining the clinical utility of amyloid PET scanning in clinical practice[8]. Dr. Gil Rabinovici, Director of the UCSF Alzheimer's Disease Research Center, has authored over 280 peer-reviewed publications and received multiple awards including the 2022 Kuhl-Lassen Award from the Society for Nuclear Medicine and Molecular Imaging[9].
Frontotemporal Dementia Program: UCSF conducts extensive research on the spectrum of FTD subtypes, including behavioral variant FTD, primary progressive aphasia (PPA), and corticobasal syndrome[10]. The center tests novel therapeutics such as veriperstat for semantic variant PPA (svPPA) and investigates TDP-43 pathology in these conditions.
Lewy Body Disease Research: The institution maintains a dedicated research program investigating the relationship between Lewy body pathology and cognitive decline, including both dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD)[11].
Young-Onset Dementia: UCSF has established a specialized program for understanding dementia occurring in patients under age 65, recognizing the unique diagnostic and therapeutic challenges in this population[12].
Neurodegenerative Disease Brain Bank: The brain bank provides researchers worldwide with access to postmortem brain tissue, enabling fundamental studies of disease mechanisms and neuropathology[4:1].
The Department of Neurology coordinates basic and clinical research across all neurological conditions, with particular strength in neurodegenerative disease research[13]:
Neuroimaging: Advanced MRI and PET imaging to visualize neurodegeneration in living patients. UCSF researchers pioneered the development of amyloid and tau PET tracers and continue to refine imaging methodologies for early detection and disease progression tracking[14][15].
Biomarker development: Identifying cerebrospinal fluid and blood markers for early detection. UCSF has been instrumental in validating blood-based biomarkers for Alzheimer's disease, including p-tau217 and p-tau181[16].
Genetics: Studying familial forms of neurodegenerative disease to identify therapeutic targets. The institution participates in international consortia including the Alzheimer's Disease Genetics Consortium and the International Parkinson's Disease Genomics Consortium.
Clinical trials: Testing new drugs and interventions for Alzheimer's, FTD, and related conditions. UCSF currently hosts multiple active clinical trials including MK-2214 for early Alzheimer's disease and trontinemab[17].
Parkinson's Disease and Movement Disorders: Under the leadership of Vice Chair for Research Dr. Robert Edwards, the department investigates the molecular and cellular basis of neurotransmitter release and its role in Parkinson's disease[18].
Dr. Gil Rabinovici serves as the Edward and Pearl Fein Distinguished Professor in Memory and Aging and Director of the UCSF Alzheimer's Disease Research Center[6:1]. His research investigates how structural, functional, and molecular brain imaging techniques can improve diagnostic accuracy in dementia and study the biology of neurodegenerative diseases, with the goal of accelerating drug development. He is the study chair of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) and New IDEAS studies, which have enrolled approximately 25,000 participants nationwide. He serves as Co-PI on ALZ-NET (Alzheimer's Network for Treatment and Diagnostics) and the Longitudinal Evaluation of Alzheimer's Disease Study (LEADS)[19]. Dr. Rabinovici has received numerous awards including the 2022 Kuhl-Lassen Award[9:1], 2015 Christopher Clark Award in Amyloid Imaging[20], and the 2012 American Academy of Neurology Research Award in Geriatric Neurology.
Dr. Robert Edwards is Vice Chair for Research in the UCSF Department of Neurology[18:1]. His research focuses on the molecular and cellular basis of neurotransmitter release and its role in Parkinson's disease. His group identified proteins that transport classical transmitters into neurosecretory vesicles, advancing understanding of the pathogenesis of movement disorders.
UCSF provides comprehensive diagnostic and treatment services for neurodegenerative diseases through its network of specialized clinics[2:2][13:1]:
UCSF researchers have made pioneering contributions to understanding neurodegenerative diseases[6:2][8:1][19:1]:
Amyloid and Tau PET Imaging: Development and validation of amyloid and tau PET imaging tracers for early diagnosis and disease staging. UCSF-led studies established the clinical utility of amyloid PET scanning in diagnostic workup of dementia[7:1][15:1].
IDEAS and New IDEAS Studies: Led the largest-ever study of amyloid PET imaging in clinical practice, demonstrating the impact of amyloid scanning on diagnostic confidence and patient management in approximately 25,000 Medicare beneficiaries.
Blood-based Biomarkers: Pioneered validation of plasma p-tau217 and p-tau181 for early detection of Alzheimer's disease pathology[16:1].
LEADS Study: Serving as Co-PI and PET Core lead for this longitudinal study of early-onset Alzheimer's disease, characterizing clinical phenotypes and biomarkers in patients with young-onset dementia.
ALZ-NET: Contributing to this NIH-funded network for standardizing data collection on Alzheimer's disease treatments in real-world clinical settings.
Genetic Risk Factors: Identification of genetic risk factors for Alzheimer's disease through genome-wide studies and characterization of novel risk genes.
FTD Subtype Characterization: Defining the clinical phenotypes and biomarker correlates of different FTD subtypes including behavioral variant FTD, svPPA, and nonfluent/agrammatic PPA.
UCSF offers extensive training in neurodegenerative disease research and clinical care[2:3]:
The institution hosts regular conferences and symposia:
UCSF currently hosts multiple active clinical trials for neurodegenerative diseases[17:1]:
Additional trials are available through ClinicalTrials.gov and the UCSF Alzheimer's Disease Research Center.
The Global Brain Health Institute (GBHI) is a partnership between UCSF and Trinity College Dublin, established with the goal of reducing the global burden of dementia[5:1]. GBHI's core programs include:
GBHI has established satellite programs in Ireland, Greece, and multiple countries in Latin America, expanding the reach of brain health training globally.
The UCSF Alzheimer's Disease Research Center (ADRC), funded by the NIH National Institute on Aging, serves as a hub for interdisciplinary research on Alzheimer's disease and related neurodegenerative disorders[3:1]. The ADRC provides:
The ADRC collaborates with 35 NIA-funded Alzheimer's Disease Research Centers nationwide, contributing to the national infrastructure for Alzheimer's disease research and ensuring representation of diverse populations in research studies.
The UCSF Neurodegenerative Disease Brain Bank is a critical resource for advancing understanding of disease mechanisms[4:2]. The brain bank:
Brain bank specimens have been used in numerous landmark studies characterizing the neuropathology of Alzheimer's disease, FTD, Lewy body disease, and other dementias.
UCSF is actively engaged in multiple national and international research networks focused on neurodegenerative diseases:
UCSF Memory and Aging Center provides extensive public education resources:
The center offers comprehensive resources for patients and families:
UCSF continues to expand its research portfolio in several emerging areas:
UCSF Official Website. 2026. ↩︎ ↩︎
UCSF Memory and Aging Center. 2026. ↩︎ ↩︎ ↩︎ ↩︎
NIH National Institute on Aging Alzheimer's Disease Research Centers Program. 2024. ↩︎ ↩︎ ↩︎
Global Brain Health Institute. 2024. ↩︎ ↩︎
Amyloid and Tau PET Imaging in Alzheimer's Disease. 2025. ↩︎ ↩︎ ↩︎
Amyloid PET: From Research to Clinical Practice. 2023. ↩︎ ↩︎
IDEAS Study: Imaging Dementia-Evidence for Amyloid Scanning. 2024. ↩︎ ↩︎
Kuhl-Lassen Award for Excellence in Brain Imaging. 2022. ↩︎ ↩︎
UCSF Department of Neurology. 2026. ↩︎ ↩︎
Tau PET Imaging in Alzheimer's and Frontotemporal Dementia. 2024. ↩︎ ↩︎
UCSF Active Clinical Trials in Neurodegenerative Diseases. 2025. ↩︎ ↩︎
Molecular Basis of Neurotransmitter Release in Parkinson's Disease. 2022. ↩︎ ↩︎
LEADS: Longitudinal Evaluation of Alzheimer's Disease Study. 2024. ↩︎ ↩︎